In the last year, Revolution Medicines generated $48.3 million in revenue and had a net loss of $56.9 million. Revolution Medicines has a market-cap of $793.5 million.
J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO.
Revolution Medicines provided the following description of their company for its IPO: ” We are a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, high-value frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. We define frontier targets as proteins that play an important role in cancer and for which there is either: (1) no approved drug that directly inhibits it, or (2) one or more approved drugs that directly inhibit it but through a mechanism of action that may not enable suppression of the full range of its biologic contributions to cancer. “.
Revolution Medicines was founded in 2014 and has 90 employees. The company is located at 700 Saginaw Drive, Redwood City, CA 94063, US and can be reached via phone at (650) 481-6801 or on the web at http://www.revmed.com.
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.